Cargando…

Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy

Detalles Bibliográficos
Autores principales:	Zhang, Zunyi, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598300/ https://www.ncbi.nlm.nih.gov/pubmed/37886181 http://dx.doi.org/10.21037/hbsn-23-352

Ejemplares similares

Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
por: Du, Jiajia, et al.
Publicado: (2023)

Novel Targeted Therapies for Advanced Cholangiocarcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review
por: Zhang, Zunyi, et al.
Publicado: (2023)

Targeted Therapies in Advanced Cholangiocarcinoma
por: Storandt, Michael H., et al.
Publicado: (2023)

New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma
por: Kawamura, Etsushi, et al.
Publicado: (2023)

Targeted therapies in cholangiocarcinoma: light at the end of the tunnel?
por: Amygdalos, Iakovos, et al.
Publicado: (2023)

Management of Craniopharyngiomas in the Era of Molecular Oncological Therapies: Not a Panacea
por: Gan, Hoong-Wei
Publicado: (2021)

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma
por: Zhao, Li-ming, et al.
Publicado: (2023)

Emerging molecular targets and therapy for cholangiocarcinoma
por: Kayhanian, Hamzeh, et al.
Publicado: (2017)

The role of FGFR inhibitors in the treatment of intrahepatic cholangiocarcinoma—unveiling the future challenges in drug therapy
por: Nishida, Naoshi
Publicado: (2023)

Development of conversion therapy for advanced hepatocellular carcinoma
por: Matsuki, Ryota, et al.
Publicado: (2023)

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy
por: Ding, Yuan, et al.
Publicado: (2021)

Ridding Canadian medicine of conversion therapy
por: Salway, Travis, et al.
Publicado: (2022)

Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer
por: Chambers, Setsuko K.
Publicado: (2022)

Apixaban for oral antithrombotic therapy: is a new era coming?
por: Zhang, Yong
Publicado: (2014)

Optimizing frontline therapy in advanced urothelial cancer
por: Kwon, Whi-An, et al.
Publicado: (2020)

Veverimer: an advance in base therapy for metabolic acidosis
por: Brady, Clayton, et al.
Publicado: (2020)

Advances and Clinical Outcomes in Hodgkin Lymphoma in the Era of Novel Therapies
por: Paviglianiti, Annalisa, et al.
Publicado: (2023)

Is there a role for stereotactic body radiation before immune checkpoint inhibitor therapy for advanced hepatocellular carcinoma?
por: Mukherjee, Sandeep
Publicado: (2023)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

Targeted Therapies for Perihilar Cholangiocarcinoma
por: Gray, Simon, et al.
Publicado: (2022)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
por: Rizzo, Alessandro
Publicado: (2021)

Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma
por: Olszanski, Anthony J.
Publicado: (2014)

Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
por: Zhang, Wei, et al.
Publicado: (2023)

Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023)

Targeted Molecular Therapy in Glioblastoma
por: Festuccia, Claudio, et al.
Publicado: (2020)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Implications of the success of EGFR-targeted therapy in advanced non–small cell lung cancer for its application to the adjuvant setting
por: Takeda, Masayuki
Publicado: (2020)

Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
por: Liu, Ziyu, et al.
Publicado: (2019)

Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy
por: Ferraro, Emanuela, et al.
Publicado: (2020)

Challenges of predicting immune checkpoint therapy responders in lung cancer
por: Marwitz, Sebastian
Publicado: (2019)

Advancing novel therapies for ichthyoses
por: Schmuth, M., et al.
Publicado: (2020)

Cytoreductive surgery in the era of targeted molecular therapy
por: Thomas, Arun Z., et al.
Publicado: (2015)

Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
por: Yu, James, et al.
Publicado: (2021)

Beyond tobacco in head and neck squamous cell cancers… Emerging era of molecular targeted therapy and virtual biopsy
por: Kant, Ravi
Publicado: (2015)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

Cancer Prevention with Molecular Targeted Therapies
por: Paleari, Laura
Publicado: (2022)

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dd03uk58p7ieo30e4l95q2th5i